Yan Liang1, Rui-Xue Leng1, Hai-Feng Pan1, Dong-Qing Ye2. 1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, PR China. 2. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, PR China. Electronic address: ydq@ahmu.edu.cn.
Abstract
BACKGROUND AND AIMS: The aim of the study was to (1) investigate the possible relationships of clinical manifestations and laboratory abnormalities with hypercoagulability in systemic lupus erythematosus (SLE) patients; (2) analyze the interaction effect between SLE disease activity and erythrocyte sedimentation rate (ESR) as well as between C3 and ESR on hypercoagulability. METHODS: The medical records of 1677 SLE patients were collected. Data on demographic characteristics, clinical manifestations, laboratory abnormalities and immunosuppressive agents use were obtained by medical record review. Coagulation score was calculated based on D-dimer and fibrinogen. RESULTS: Coagulation score was associated with the presence of lupus nephritis (β-coefficient [β]: 0.046; 95% confidence interval [CI]: 0.021-0.071; p <0.001), pleuritis (β: 0.113; 95% CI: 0.074-0.151; p <0.001), pericarditis (β: 0.075; 95% CI: 0.031-0.119; p = 0.001), fever (≥38°C) (β: 0.119; 95% CI: 0.083-0.155; p <0.001), active disease (β: 0.070; 95% CI: 0.044-0.096; p <0.001) and increased ESR (β: 0.199; 95% CI: 0.171-0.226; p <0.001) in multivariate linear regression models. A significant effect on coagulation score by the interaction between SLE disease activity and ESR was found (p <0.001). In contrast, there was no significant interaction effect between C3 and ESR (p = 0.248). CONCLUSIONS: Lupus nephritis, pleuritis, pericarditis, fever (≥38°C), active disease and increased ESR were associated with hypercoagulability in SLE. There was a significant interaction between active disease and increased ESR for hypercoagulability in SLE.
BACKGROUND AND AIMS: The aim of the study was to (1) investigate the possible relationships of clinical manifestations and laboratory abnormalities with hypercoagulability in systemic lupus erythematosus (SLE) patients; (2) analyze the interaction effect between SLE disease activity and erythrocyte sedimentation rate (ESR) as well as between C3 and ESR on hypercoagulability. METHODS: The medical records of 1677 SLEpatients were collected. Data on demographic characteristics, clinical manifestations, laboratory abnormalities and immunosuppressive agents use were obtained by medical record review. Coagulation score was calculated based on D-dimer and fibrinogen. RESULTS: Coagulation score was associated with the presence of lupus nephritis (β-coefficient [β]: 0.046; 95% confidence interval [CI]: 0.021-0.071; p <0.001), pleuritis (β: 0.113; 95% CI: 0.074-0.151; p <0.001), pericarditis (β: 0.075; 95% CI: 0.031-0.119; p = 0.001), fever (≥38°C) (β: 0.119; 95% CI: 0.083-0.155; p <0.001), active disease (β: 0.070; 95% CI: 0.044-0.096; p <0.001) and increased ESR (β: 0.199; 95% CI: 0.171-0.226; p <0.001) in multivariate linear regression models. A significant effect on coagulation score by the interaction between SLE disease activity and ESR was found (p <0.001). In contrast, there was no significant interaction effect between C3 and ESR (p = 0.248). CONCLUSIONS:Lupus nephritis, pleuritis, pericarditis, fever (≥38°C), active disease and increased ESR were associated with hypercoagulability in SLE. There was a significant interaction between active disease and increased ESR for hypercoagulability in SLE.
Authors: Rustem I Litvinov; Rosa M Nabiullina; Laily D Zubairova; Mileusha A Shakurova; Izabella A Andrianova; John W Weisel Journal: Front Immunol Date: 2019-07-16 Impact factor: 7.561